We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.38% | 1,305.00 | 1,305.00 | 1,306.00 | 1,315.00 | 1,300.00 | 1,300.00 | 3,488,246 | 15:30:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 10.98 | 53.89B |
Date | Subject | Author | Discuss |
---|---|---|---|
10/10/2024 09:28 | Great settlement for GSK $2.2bn A bargain "Worries had mounted over how many billions GSK might have to pay, with analyst estimates reaching $8 billion last year and even $45 billion in 2022. That has weighed heavily on its share price, with tens of billions of dollars wiped off the market value of companies linked to the drug. Shares recovered as the cases were eventually settled. Bloomberg | geckotheglorious | |
10/10/2024 09:23 | Yes now good value, investors hate uncertainty, now settled, good news. | montyhedge | |
10/10/2024 08:52 | Even with today's settlement news and 6% jump in share price (so far), GSK continues to be seriously undervalued and remains an outstanding BUY. | tradermichael | |
10/10/2024 08:39 | GSK's investment case has significantly improved following its settlement of liability cases related to its discontinued Zantac drug, Deutsche Bank analysts Emmanuel Papadakis and Niall Alexander say in a note. The resolve is a surprising and positive twist to the investment case as it came sooner than expected and should ease investors concerns that had weighed on the shares, they say. Even with the share boost following the news, the pharma giant still seems undervalued based on its projected earnings for 2025, they add. | dplewis1 | |
10/10/2024 08:16 | Anyone re-investing their GSK dividend (paid today)? | tradermichael | |
10/10/2024 08:00 | In corporate news, GSK surged after agreeing to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of markets on Wednesday, the pharmaceuticals firm said it had reached an agreement with 10 firms who represent 93% of the Zantac (ranitidine) state court product liability cases pending against it in the US. GSK also said it had agreed to pay $70m to resolve a whistleblower complaint by a laboratory called Valisure, which alleged that the pharmaceuticals company had defrauded the US government by concealing the cancer risks of heartburn drug Zantac for decades. | tradermichael | |
10/10/2024 07:54 | +6% and a dividend paid out today... | mister md | |
10/10/2024 07:10 | Indeed, looks like a positive view from market | simon8 | |
10/10/2024 07:08 | Opening USD4bn or so up seems to indicates market relief. | patientcapital | |
10/10/2024 06:44 | What happened to the Delaware supreme court appeal, have I missed something? Not sure how price will react but only 15 mins to find out... | simon8 | |
10/10/2024 05:29 | GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer. The British pharmaceutical giant said Wednesday that it had struck agreements with 10 plaintiff firms aimed at resolving 93%, or about 80,000, of pending Zantac lawsuits in the country for up to $2.2 billion. Write to singaporeeditors@dow | waldron | |
09/10/2024 22:14 | USD2.2bn seems a relative bargain compared with the 5 or so being speculated about a few months ago. On balance good news. | patientcapital | |
09/10/2024 20:28 | It's the USA. Pay to settle or we drag you out for years for our own pockets, not the plaintiff. | dope007 | |
09/10/2024 20:25 | Settlement of Zantac cases for up to $2.2 billion. I think this is wrong and the company has managed this really badly. I have sympathy with anyone with cancer but the 16 studies showed clearly that Zantac was not the cause. Despicable lawyers. | rikky72 | |
09/10/2024 20:01 | All eyes are on the budget now. FTSE in a holding pattern. | pander45 | |
09/10/2024 19:45 | Get a result in the appeal and £19-20 a lot more likely than £13! | rikky72 | |
09/10/2024 19:44 | ADRs are up 6%, hardly soaring. Which is handy because it might be more of a slow burn up. | hpcg | |
09/10/2024 19:42 | Up 6% stateside, so expecting that and some tomorrow here | dope007 | |
09/10/2024 18:35 | Pander isn't getting his 13 quid that's for sure | dplewis1 | |
09/10/2024 18:21 | Shame day b4 divi paid out. Will be getting less shares tomorrow than if received today | watfordhornet | |
09/10/2024 18:04 | Dynamite.... c £1.7Billion (TG for strong pound). Cheap, cheap, cheap. And knock off £500 million off for potential legal fee savings over the next few years, and tax write offs on the payment. GSK should be £20 given peer valuations. | cumnor | |
09/10/2024 18:04 | Pay $2.2 billion to resolve approx 80,000 cases, works out around $27,500 per case, seems cheap to me, onwards and upwards....hopefully | wm2020 | |
09/10/2024 18:03 | Looks like a big rise tomorrow up nearly 8 percen in USA | timothyo2 | |
09/10/2024 18:01 | Kill or fill at £16.00? | tahmina1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions